rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.
Activity of rifampin against 129 Streptococcus mitis isolates obtained from patients with hematologic cancer was investigated. One hundred twenty-five strains were susceptible to rifampin, and 4 were resistant (MIC = 32 to 64 microg/ml). Resistance to rifampin was related to mutations in the rpoB gene: His(526)Asn in three strains and His(526)Asp in one strain.
Achour
Wafa
W
Laboratoire du Centre National de Greffe de Moelle Osseuse, 1006 Tunis, Tunisia.
Guenni
Olfa
O
Fines
Marguerite
M
Leclercq
Roland
R
Ben Hassen
Assia
A
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D017931:DNA Primers; D012321:DNA-Directed RNA Polymerases / Q000235:genetics*; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics; D009503:Neutropenia / Q000382:microbiology; D012293:Rifampin / Q000494:pharmacology*; D020539:Sequence Analysis, Protein; D013290:Streptococcal Infections / Q000382:microbiology*; D034361:Streptococcus mitis / Q000187:drug effects*
D000904:Antibiotics, Antitubercular; D017931:DNA Primers; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit; D012293:Rifampin